FTC Final Order with Baxter International and Claris Lifesciences Preserves U.S. Competition for the

Federal Trade Commission press release ------- Following a public comment period, the Federal Trade Commission has approved a final order designed to remedy the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business. To learn more click on the picture below to read the release.